Clinical trial
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
NCT00093457 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00093457 |
|---|---|
| Title | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer |
| Official title | A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 28 |
| Start date | Aug 10, 2004 |
| Primary completion | Sep 28, 2006 |
| Completion | Jan 18, 2011 |
| First posted | Oct 8, 2004 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: